The landscape of federal medical cannabis policy in the United States is undergoing significant re-evaluation, with the Department of Justice (DOJ) reportedly reconsidering its approach to prosecuting individuals for gun possession based solely on marijuana use. This potential shift, indicated by Acting Attorney General Todd Blanche, aligns with broader discussions within the Trump administration regarding firearms regulations and comes amidst diverse legislative and scientific developments impacting the cannabis and hemp sectors.
Federal Policy Shifts and Regulatory Debates
Acting Attorney General Todd Blanche has stated that the Department of Justice is re-evaluating whether to continue prosecuting marijuana consumers for possessing firearms. This reconsideration is part of the Trump administration’s broader initiative to reduce regulatory burdens on gun owners and businesses, as reported by Marijuana Moment.
Concurrently, President Donald Trump’s nominee for surgeon general, Nicole Saphier, has acknowledged the “potential benefits” of medical cannabis, despite previously expressing general concerns about marijuana use. This nuanced stance from a high-level health official underscores the ongoing debate surrounding cannabis’s role in public health.
In a move that challenges the administration’s reform efforts, the House Appropriations Subcommittee on Commerce, Justice, Science, and Related Agencies approved a spending bill containing a rider designed to block any marijuana rescheduling action by the Department of Justice. Separately, the House Appropriations Committee approved a spending bill and an attached report expressing concerns about health risks associated with cannabis-derived products, while simultaneously encouraging research into the potential benefits of psychedelics.
Industrial Hemp and Agricultural Legislation
The House of Representatives recently passed a Farm Bill that includes provisions aimed at reducing regulatory burdens for industrial hemp producers. However, the bill notably lacks any language to delay or revise the federal recriminalization of hemp THC products, which is currently scheduled to take effect later this year. This omission has been a point of concern for industry stakeholders, with former Acting Homeland Security Secretary Chad Wolf authoring an op-ed urging Congress not to reverse the scheduled recriminalization, as detailed by Marijuana Moment.
The ongoing legislative discussions highlight the complex regulatory environment for industrial hemp, balancing agricultural support with concerns over intoxicating hemp-derived cannabinoids.
Medical Cannabis Access and Research Developments
On the research front, the National Institute on Drug Abuse (NIDA) Director Nora Volkow recently authored a blog post exploring the role of artificial intelligence in addressing substance use and public health challenges. This signals a growing interest in leveraging advanced technologies for public health interventions.
State-level regulators are also preparing for potential federal shifts. Hawaii’s top medical cannabis regulator indicated that federal marijuana rescheduling would likely ease barriers to research, potentially opening new avenues for scientific inquiry into cannabis. Furthermore, the New Hampshire Therapeutic Cannabis Medical Oversight Board is scheduled to hold a hearing on May 20 to consider adding glaucoma and hepatitis C as qualifying conditions for therapeutic cannabis access.
Scientific studies continue to explore the potential of cannabis. For example, one study indicated that cannabinoids found in Cannabis sativa stems demonstrated properties of interest for cancer research, while another study observed that CBD had an effect on age-associated cognitive decline in a mouse model, as reported by Marijuana Moment. These findings contribute to the growing body of evidence supporting the medical applications of cannabinoids.
In related developments concerning therapeutic substances, the Senate Veterans’ Affairs Committee held a hearing on a psychedelics research and access bill. While the Department of Veterans Affairs (VA) supported the “intent” of the legislation, it did not endorse its specific provisions. Senator Ruben Gallego (D-AZ) noted that the current administration has shown improved engagement with psychedelics and veterans compared to the previous one.
Industry Movements and State-Level Initiatives
In the business sector, Vireo Growth Inc. is reportedly acquiring FLUENT Corp., indicating continued consolidation within the cannabis industry. Verano Holdings Corp. reported quarterly net revenue of US$208.2 million, alongside a net loss of US$17.8 million, as per Marijuana Moment. These figures reflect the dynamic financial landscape for publicly traded cannabis companies.
At the state level, Minnesota regulators are actively accepting applications for cannabis farmer training and loan grant programs, initiatives designed to support the agricultural and entrepreneurial aspects of the cannabis industry. This demonstrates proactive state efforts to foster growth and provide resources for cultivators.
Disclaimer: This article is for informational purposes only and does not constitute medical advice. Hemp Gazette does not provide medical recommendations, diagnoses, or treatment plans. Always consult a qualified healthcare practitioner before making any decisions regarding your health or any medical condition. Statements concerning the therapeutic uses of hemp, cannabis, or cannabinoid-derived products have not been evaluated by Australia’s Therapeutic Goods Administration (TGA). Medicinal cannabis products in Australia are accessed via prescription pathways under TGA regulation.
